Aortica Corporation was founded to design, manufacture, and market tools for treatment of patients with AAA disease who have aortic anatomy that limits their treatment options. While EVAR has become a highly desirable option for treatment of AAA disease, approximately 40% of patients are not candidates for EVAR because their aortic anatomy is structured in a manner that does not allow an endograft to be anchored properly without blocking blood flow to vital organs. These patients face either open surgery or may be treated sub-optimally with standard EVAR.
Personalized Vascular Therapy
Our Mission & Vision
We envision a future where Personalized Vascular Therapy becomes the standard of care, allowing more physicians to treat more patients with complex AAA disease. We will achieve our objectives through both invention and innovation – developing and continuously improving therapeutic options that deliver minimally invasive, highly effective treatment options to all patients in our target markets.